Evotec SE Business Summary

Evotec SE operates a hybrid business model designed to capture value across the entire drug discovery and development lifecycle. The company generates revenue through two primary segments: EVT Execute, which provides high-end fee-for-service integrated R&D solutions, and EVT Innovate, which focuses on internal platform development and partnered programs that yield milestone payments, royalties, and equity stakes. A critical growth engine is its "Just – Evotec Biologics" division, which utilizes AI-driven continuous manufacturing technology to optimize the production of complex biologics. Evotec competes directly with major Contract Research Organizations (CROs) and CDMOs such as Charles River Laboratories, WuXi AppTec, and Lonza. While these competitors often focus on scale and capacity, Evotec differentiates itself as a "co-innovation" partner, leveraging its proprietary PanOmics and PanHunter data platforms to offer high-density biological insights rather than purely transactional services. Founded in 1993 by a group of scientists including Nobel laureate Manfred Eigen, Evotec is currently led by CEO Christian Wojczewski, who took the helm in 2024 to drive operational excellence following a successful tenure at Mediq and Linde. The executive leadership includes Chief Scientific Officer Cord Dohrmann, a veteran of the Max Planck Institute and DeveloGen, and Chief Operating Officer Craig Johnstone, who manages the firm’s global integrated R&D sites. Financial strategy is overseen by Laetitia Szaller, who serves as a key architect of the company’s corporate development and capital allocation. The company is backed by a sophisticated investor base, including major stakes held by Novo Holdings A/S and Mubadala Investment Company, while its Supervisory Board is chaired by Iris Löw-Friedrich, ensuring deep strategic alignment with the global pharmaceutical industry.